U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07364305) titled 'HAIC Combined With Immune Therapy for Advanced, Non-Resectable ICC' on Jan. 03.
Brief Summary: Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis. The aim of this study is to investigate the efficacy and safety of GP-HAIC combined with immunosuppressants in the treatment of initially unresectable ICC patients, as well as its role in conversion therapy. A prospective study was conducted on the data of locally advanced unresectable ICC patients receiving GC-HAIC combined with immunosuppressive therapy, evaluating the treatment efficacy and safety.
Study Start Date: Jan. 01, 2025
Study Type: INTERVENTIONAL
Condition:
ICC
Ad...